Breaking Finance News

Leerink Partners upgraded Tesaro (NASDAQ:TSRO) from Mkt Perform to Outperform in a report released today.

Leerink Partners has upgraded Tesaro (NASDAQ:TSRO) from Mkt Perform to Outperform in a report released on Wednesday November 15, 2017.

Previously on Monday October 23, 2017, Barclays reported on Tesaro (NASDAQ:TSRO) increased the target price from $0.00 to $135.00. At the time, this indicated a possible upside of 0.16%.

Just yesterday Tesaro (NASDAQ:TSRO) traded -2.10% lower at $115.77. Tesaro’s 50-day moving average is $119.39 and its 200-day moving average is $131.99. The last closing price is down -16.63% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the same time period. 480,616 shares of TSRO traded hands, down from an average trading volume of 809,809

Recent Performance Chart


Tesaro has 52 week low of $106.64 and a 52 week high of $192.94 and has a market capitalization of $0.

A total of 10 analysts have released a report on Tesaro. Eight firms rating the stock a strong buy, 4 firms rating the stock a buy, 0 firms rating the stock a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $89.00.

Brief Synopsis About Tesaro (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.